原发性肝癌应用三氧化二砷治疗的临床研究

目的：观察原发性肝癌应用三氧化二砷（As2O3）治疗的临床疗效。方法：在知情同意的情况下,采用动脉灌注给药,应用As2O320mg/d,连续应用5d为1个疗程,共进行6个疗程,每个月进行B超或CT检查。结果：三氧化二砷治疗6个疗程后,38例肿瘤体积缩小或不变,有效率为71.6%。有48例获得随访,最长存活时间23个月,1年生存率为60.2%。结论：As2O3连续动脉灌注给药对不适合手术治疗的原发性肝癌患者有很好的临床治疗效果。

Clinical study of arsenic trioxide in the treatment of primary hepatocellular carcinoma

ObjectiveTo evaluate the clinical effect and mechanism of arsenic trioxide(As2O3)in the treatment of primary hepatocellular carcinoma.MethodFifty-three patients with primary hepatocellular carcinoma hospitalized from January 2002 to January 2004 were studied(male 37,female 16,age 35～72 years old,average 55.7 years old).In the situation of agreement,20mg As2O3 was given by artery perfusion qd for 5 days each treatment course and was repeated for 6 times.Every month they were examined by B ultrasound or CT.ResultsAfter 6 treatment courses of As2O3,the tumor volume of 38 patients reduced or invariable,the efficiency was 71.6%.Forty-eight patients were made a follow-up visit,the longest survival time was 23 months,a year survival rate was 60.2%.ConclusionAs2O3 artery perfusion therapy has a good clinical effect in the treatment of primary hepatocellular carcinoma which is unfit for operation.